NeuroMetrix Inc. is a healthcare company that specializes in developing advanced medical technologies to improve the management of chronic pain and diabetes-related conditions
Their innovative products include non-invasive diagnostic and therapeutic devices that utilize neurostimulation and electrophysiology. By focusing on enhancing patient outcomes, the company aims to provide healthcare professionals with tools that facilitate accurate diagnosis and effective treatment strategies, ultimately alleviating the burden of pain and improving the quality of life for individuals suffering from these chronic conditions.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeuroMetrix, Inc. (NasdaqCM: NURO) to electroCore, Inc. Under the terms of the proposed transaction, shareholders of NeuroMetrix will receive one non-tradeable contingent value right (the “CVR”) per share of NURO common stock owned. Each CVR will represent the right to receive (i) certain future net proceeds from any divestiture of NURO’s DPNCheck platform that is consummated prior to the closing of the transaction with electroCore and (ii) certain royalties, up to an aggregate maximum of $500,000, on net sales of prescription Quell® products over the first two years following the closing of the transaction. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeuroMetrix, Inc. (NASDAQNURO) to electroCore, Inc. is fair to NeuroMetrix shareholders.
For decades, opioids have been the go-to medication for managing post-operative and other types of pain. However, the tide is turning as the devastating consequences of opioid addiction become increasingly clear. Athletes, known for pushing their bodies to the limit, are at the forefront of this shift, seeking out innovative, non-opioid solutions to manage pain after surgery and expedite healing. Their experiences are raising public awareness – and investor attention – about alternative treatment options and paving the way for a future where powerful painkillers are not the only answer.
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Earlier today Echo Lake Capital sent a letter to the Board of Directors of Neurometrix, Inc. (NASDAQNURO). The letter listed the top ten reasons why the Board should immediately fire Shai Gozani, the company's longstanding Chairman and CEO. The reasons include (i) NURO's stock price has declined 99% since the IPO, (ii) while shareholders have suffered massive losses, Gozani has received over $10 million of compensation, (iii) Gozani was charged by the Federal Trade Commission for various wrongdoings at NURO, (iv) Gozani apparently personally paid $4 million to the FTC as part of a settlement, and (v) Gozani's decision to dilute shareholders by having NURO issue shares at prices significantly below net cash.
Gainers NeuroBo Pharmaceuticals (NASDAQNRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
